FDA awards a Commissioner’s National Priority Voucher to Johnson & Johnson for teclistamab in combination with daratumumab

The FDA awarded a Commissioner’s National Priority Voucher to Johnson & Johnson for teclistamab in combination with daratumumab for relapsed/refractory multiple myeloma.

The FDA selected this regimen for a Voucher following their data presentation at ASH. FDA leaders read the study, consulted with internal experts, and the following day contacted the company to discuss a national priority voucher.

‍

Source: Press Release